Search

Search Constraints

You searched for: Author/Creator Klearman, Micki

Search Results

1. 272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. (12th April 2019)

2. 351. EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. (29th March 2019)

4. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Issue 1 (27th December 2019)

5. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study. Issue 6 (28th April 2017)

6. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Issue 10 (27th November 2015)

8. Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Issue 8 (3rd July 2019)

10. O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial. (12th April 2019)